HOME >> BIOLOGY >> NEWS
Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis

Wilex AG, Munich, Germany, and Fox Chase Cancer Center, Philadelphia, Pa., announced today the start of a clinical trial with a novel compound, WX-UK1, targeting tumor cell invasion and metastasis. This Phase I trial marks the start of an innovative collaboration between the U.S. government, an academic research center (Fox Chase) and a biotech firm (Wilex) to rapidly move a laboratory discovery to the clinic for use in patients.

This is the first of two clinical trials with Wilex's compound WX-UK1 at Fox Chase funded by a US$ 3.9 million grant from the U.S. Department of Defense (DoD) Breast Cancer Research Program to study the potential of this agent as a breast cancer therapeutic in the USA.

WX-UK1 is a non-cytotoxic small molecule that belongs to a new class of drugs. In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting the urokinase Plasminogen Activator (uPA) system.

"The pre-clinical research with WX-UK1 provided strong data warranting a clinical trial to pursue the possible benefit this drug may have in the treatment of breast cancer," said Lori J. Goldstein, M.D., principal investigator of this study and director of Fox Chase's Breast Evaluation Center and leader of the Breast Cancer Research Program at Fox Chase. "The DOD-Wilex-Fox Chase collaboration is an example of how government, private industry, and academia can work together to bring promising research from the laboratory to the clinic quicker than traditional avenues."

"Unlike conventional chemotherapeutic agents, WX-UK1 is focused on a biological target directly connected to cancer progression, and, therefore offers an entirely new mechanism of action," said Prof. Olaf G. Wilhelm, MD, Chief Executive Officer of Wilex. "It is our goal to develop WX-UK1 for use in combination with chemotherapy. With Fox Chase Cancer Center, we have a highly experienced and capable partner for the clinical development of WX-UK1 in the USA".


'"/>

Contact: Karen C. Mallet
k_carter@fccc.edu
215-728-2700
Fox Chase Cancer Center
25-May-2004


Page: 1 2

Related biology news :

1. Fox Chase Cancer Centers Alfred Knudson Jr. named 2004 Kyoto Prize winner
2. Fox Chase discovery may help physicians diagnose, treat devastating childhood disease
3. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
4. Fox Chase Cancer Center researchers identify significant smoking-induced genetic alteration
5. Fox Chase Cancer Center research reveals how COX-2 causes ovarian cancer
6. Fox Chase Cancer Center research shows kidney cancer can be diagnosed in urine
7. Fox Chase Cancer Center researcher develops new model for studying prions mad cow disease
8. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Fox Chase Cancer Center researchers make significant discovery about function of p53
11. Fox Chase Cancer Center receives grant to study possible link between measles vaccine and autism

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2019)... ... June 04, 2019 , ... ... the appointment of Susan Murphy as the new President of Molecular Devices, replacing ... Molecular Devices’ parent company, Danaher Corporation. , Since joining Molecular Devices in a ...
(Date:6/1/2019)... FREDERICK, Md. (PRWEB) , ... May 31, 2019 ... ... legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series ... WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and ...
(Date:5/31/2019)... ... May 31, 2019 , ... The OilComm ... Houston, TX, announced today that Ben Reiter, Senior Writer at Sports Illustrated and ... October 3rd.     , Reiter predicted the Houston Astros would win the MLB championship ...
Breaking Biology News(10 mins):
(Date:5/14/2019)... JOLLA, Calif. (PRWEB) , ... May 14, 2019 , ... ... an office expansion, effectively doubling its space from 2,500 to 5,000 square feet. ... SneakPeek Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... Organization for Standardization ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ... In addition, REPROCELL USA Inc. aims to enhance customer satisfaction through the ...
(Date:4/25/2019)... ... ... an albino, deaf Great Dane. His owners rescued him when he was four months old ... hearing impairment, he was always an active and playful pup. Frank bonded with his brother, ... the two grew, playtime became rougher and Frank ended up injuring his right rear leg. ...
(Date:4/15/2019)... ... April 15, 2019 , ... ... of a $2 million bench plant expansion to increase production of methylene malonate ... the design and construction of Sirrus’ full-scale production facility, which is scheduled to ...
Breaking Biology Technology:
Cached News: